Conservative Management of Vulvar Cancer-Where Should We Draw the Line?

被引:0
|
作者
Hacker, Neville F. [1 ]
Barlow, Ellen L. [2 ]
机构
[1] Univ New South Wales, Fac Med & Hlth, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia
[2] Univ New South Wales, Fac Med & Hlth, Sch Women & Childrens Hlth, Gynaecol Canc Res Grp, Sydney, NSW 2052, Australia
关键词
vulvar cancer; radical vulvectomy; radical local excision; pelvic lymph node dissection; sentinel node biopsy; surgical margins; ultrasonic groin surveillance; SQUAMOUS-CELL CARCINOMA; PATHOLOGICAL MARGIN DISTANCE; TUMOR-FREE MARGINS; LYMPH-NODE BIOPSY; STAGE-I CARCINOMA; TERM-FOLLOW-UP; PROGNOSTIC-FACTORS; LOCAL RECURRENCE; INGUINAL LYMPHADENECTOMY; EPIDERMOID CARCINOMA;
D O I
10.3390/cancers16172991
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vulvar cancer is a rare disease, and cure rates were low until the mid-20th century. The introduction of an en bloc radical vulvectomy and bilateral groin and pelvic lymph node dissection saw them rise from 15-20% to 60-70%. However, this very radical surgery was associated with high physical and psychological morbidity. Wounds were usually left open to granulate, and the average post-operative hospital stay was about 90 days. Many attempts have been made to decrease morbidity without compromising survival. Modifications that have proven to be successful are as follows: (i) the elimination of routine pelvic node dissection, (ii) the use of separate incisions for groin dissection, (iii) the use of unilateral groin dissection for lateral, unifocal lesions, (iv) and radical local excision with 1 cm surgical margins for unifocal lesions. Sentinel node biopsy with ultrasonic groin surveillance for patients with node-negative disease has been the most recent modification and is advocated for patients whose primary cancer is <4 cm in diameter. Controversy currently exists around the need for 1 cm surgical margins around all primary lesions and on the appropriate ultrasonic surveillance for patients with negative sentinel nodes.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [1] Safety Expenditure: where should we draw the Line?
    Jones-Lee, Mike
    SAFETY-CRITICAL SYSTEMS: PROBLEMS, PROCESS AND PRACTICE, 2009, : 55 - 67
  • [3] The TCA "tox screen": Where should we draw the line?
    Johnson-Arbor, K.
    Goldstein, R.
    McKay, C.
    Wu, A.
    Smith, A.
    CLINICAL TOXICOLOGY, 2006, 44 (05): : 736 - 736
  • [4] Hello Dolly! Where should we draw the line on cloning?
    Kuhse, H
    SEARCH, 1997, 28 (03): : 86 - 88
  • [5] Where we draw the line
    Freeman, JW
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (06): : 671 - 672
  • [6] Estrogen receptor β -: which one and where should we draw the line?
    Shaaban, AM
    Speirs, V
    HUMAN PATHOLOGY, 2006, 37 (04) : 498 - 498
  • [7] Folic acid and cancer-where are we today?
    Miller, Joshua W.
    Ulrich, Cornelia M.
    LANCET, 2013, 381 (9871): : 974 - 976
  • [8] Immunotherapy in Ovarian Cancer-Where Are We Going?
    Markman, Maurie
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (02) : 13 - 15
  • [9] Where do we draw the line?
    Gornall, Jonathan
    BRITISH MEDICAL JOURNAL, 2007, 334 (7588): : 285 - 289
  • [10] Natural experiments and observational studies: where and how should we draw the line?
    Craig, P.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2017, 27 : 303 - 303